![]() ![]() Sarepta has a market cap of $13.9 billion. The FDA is set to make a final decision on SRP-9001 at its AdCom meeting on May 29. The shares surged more than 30% on the news on Monday. Sarepta Therapeutics ( SRPT) is another potential takeover target after an FDA advisory committee backed the agency’s accelerated approval for SRP-9001 targeted at certain patients with Duchenne muscular dystrophy. Blueprint has a market cap of $3.3 billion. The company has an important PDUFA date for expanding the indication for the drug on Wednesday. Interest for the company is expected to increase after the July data is released.īlueprint Medicines ( BPMC) is an another potential takeover candidate and it has a commercial drug called Ayvakit, according to Nierengarten. Argenx ( ARGX) is working with JPMorgan to look at its options in the event of a takeover bid for the $23 billion company. The Wedbush analyst's comments came before a Bloomberg story on Tuesday indicated several drugmakers have been studying the Dutch biotech company and have it on top of their wish lists. ![]() An importantly they have multiple clinical trials set up to expand the indication beyond myasthenia gravis."Īrgenx has a key data point for a disease called CIDP in July, according to Nierengarten. "It did $400 million last year and we think it can do over $1 billion this year. "It has has a great launch so far," Nierengarten explained. Nierengarten sees Dutch biotech Argenx ( ARGX) as a likely takeover target due to the success of its drug Vyvgart, which is therapy for neuromuscular disease myasthenia gravis. They have been robust year-to-date and I think they should continue for the rest of the year." "Obviously it's an attractive valuation for acquirers at this point. "I think this really points to a bottom for the small/midcap sector," Nierengarten said in an interview with CNBC on Monday. Main Street pays a monthly dividend of 23 cents per share, with an annual yield of 6.9. Year-to-date there have been over $70 billion announced acquisitions in the biotech space and for the entire year last year there was just just under $70 billion in deals announced, according to Wedbush analyst David Nierengarten. In less than 16 years, the stock has paid out an impressive 37.56 per share in cumulative dividends. Marcelo Ricardo Daros/iStock via Getty ImagesĪrgenx ( NASDAQ: ARGX) Blueprint Medicines ( NASDAQ: BPMC) and Sarepta Therapeutics ( NASDAQ: SRPT) are likely takeover targets in the biotech sector, according to a Wedbush analyst. ![]()
0 Comments
Leave a Reply. |